• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mad2过表达揭示了TRIP13在有丝分裂退出中的关键作用。

Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.

作者信息

Marks Daniel Henry, Thomas Rozario, Chin Yvette, Shah Riddhi, Khoo Christine, Benezra Robert

机构信息

Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.

出版信息

Cell Rep. 2017 May 30;19(9):1832-1845. doi: 10.1016/j.celrep.2017.05.021.

DOI:10.1016/j.celrep.2017.05.021
PMID:28564602
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5526606/
Abstract

The mitotic checkpoint ensures proper segregation of chromosomes by delaying anaphase until all kinetochores are bound to microtubules. This inhibitory signal is composed of a complex containing Mad2, which inhibits anaphase progression. The complex can be disassembled by p31 and TRIP13; however, TRIP13 knockdown has been shown to cause only a mild mitotic delay. Overexpression of checkpoint genes, as well as TRIP13, is correlated with chromosomal instability (CIN) in cancer, but the initial effects of Mad2 overexpression are prolonged mitosis and decreased proliferation. Here, we show that TRIP13 overexpression significantly reduced, and TRIP13 reduction significantly exacerbated, the mitotic delay associated with Mad2 overexpression, but not that induced by microtubule depolymerization. The combination of Mad2 overexpression and TRIP13 loss reduced the ability of checkpoint complexes to disassemble and significantly inhibited the proliferation of cells in culture and tumor xenografts. These results identify an unexpected dependency on TRIP13 in cells overexpressing Mad2.

摘要

有丝分裂检查点通过延迟后期直到所有动粒都与微管结合,来确保染色体的正确分离。这种抑制信号由包含Mad2的复合物组成,该复合物抑制后期进程。该复合物可被p31和TRIP13拆解;然而,已表明敲低TRIP13仅会导致轻微的有丝分裂延迟。检查点基因以及TRIP13的过表达与癌症中的染色体不稳定性(CIN)相关,但Mad2过表达的初始效应是有丝分裂延长和增殖减少。在这里,我们表明,TRIP13过表达显著降低,而TRIP13减少则显著加剧了与Mad2过表达相关的有丝分裂延迟,但对微管解聚诱导的延迟没有影响。Mad2过表达和TRIP13缺失的组合降低了检查点复合物的拆解能力,并显著抑制了培养细胞和肿瘤异种移植中细胞的增殖。这些结果确定了过表达Mad2的细胞对TRIP13存在意想不到的依赖性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/1336b2b16ab3/nihms877338f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/8077ef9d909c/nihms877338f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/7ac83a676b5e/nihms877338f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/d2b23a4424f3/nihms877338f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/9a05adb02b02/nihms877338f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/2ac1e6b890ab/nihms877338f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/1336b2b16ab3/nihms877338f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/8077ef9d909c/nihms877338f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/7ac83a676b5e/nihms877338f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/d2b23a4424f3/nihms877338f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/9a05adb02b02/nihms877338f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/2ac1e6b890ab/nihms877338f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3476/5526606/1336b2b16ab3/nihms877338f6.jpg

相似文献

1
Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.Mad2过表达揭示了TRIP13在有丝分裂退出中的关键作用。
Cell Rep. 2017 May 30;19(9):1832-1845. doi: 10.1016/j.celrep.2017.05.021.
2
Mode of interaction of TRIP13 AAA-ATPase with the Mad2-binding protein p31comet and with mitotic checkpoint complexes.TRIP13 AAA-ATP酶与Mad2结合蛋白p31彗星以及有丝分裂检查点复合物的相互作用模式。
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11536-40. doi: 10.1073/pnas.1515358112. Epub 2015 Aug 31.
3
TRIP13 Functions in the Establishment of the Spindle Assembly Checkpoint by Replenishing O-MAD2.TRIP13 通过补充 O-MAD2 来发挥作用,从而建立纺锤体装配检查点。
Cell Rep. 2018 Feb 6;22(6):1439-1450. doi: 10.1016/j.celrep.2018.01.027.
4
Mechanistic insight into TRIP13-catalyzed Mad2 structural transition and spindle checkpoint silencing.深入了解 TRIP13 催化 Mad2 结构转变和纺锤体检查点沉默的机制。
Nat Commun. 2017 Dec 5;8(1):1956. doi: 10.1038/s41467-017-02012-2.
5
TRIP13 Regulates Both the Activation and Inactivation of the Spindle-Assembly Checkpoint.TRIP13调节纺锤体组装检查点的激活与失活。
Cell Rep. 2016 Feb 9;14(5):1086-1099. doi: 10.1016/j.celrep.2016.01.001. Epub 2016 Jan 28.
6
Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13.细胞周期检查点蛋白 MAD2 重塑的机制由 ATPase TRIP13 介导。
Nature. 2018 Jul;559(7713):274-278. doi: 10.1038/s41586-018-0281-1. Epub 2018 Jul 4.
7
Thyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing protein.甲状腺激素受体相互作用蛋白13(TRIP13)AAA-ATP酶是一种新型的有丝分裂检查点沉默蛋白。
J Biol Chem. 2014 Aug 22;289(34):23928-37. doi: 10.1074/jbc.M114.585315. Epub 2014 Jul 10.
8
TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.TRIP13损害有丝分裂检查点监测,与多发性骨髓瘤的不良预后相关。
Oncotarget. 2017 Apr 18;8(16):26718-26731. doi: 10.18632/oncotarget.14957.
9
TRIP13 and APC15 drive mitotic exit by turnover of interphase- and unattached kinetochore-produced MCC.TRIP13 和 APC15 通过有丝分裂后期 MCC 的周转来驱动有丝分裂后期的退出,该 MCC 由间期和未连接的着丝粒产生。
Nat Commun. 2018 Oct 19;9(1):4354. doi: 10.1038/s41467-018-06774-1.
10
Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet).由 AAA-ATP 酶 TRIP13 和 p31(comet)的联合作用将有丝分裂检查点复合物解体。
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12019-24. doi: 10.1073/pnas.1412901111. Epub 2014 Aug 4.

引用本文的文献

1
Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.通过分子建模和生物测定发现靶向TRIP13的新型抗骨髓瘤药物
RSC Med Chem. 2025 May 6. doi: 10.1039/d4md01008f.
2
Advancing the development of TRIP13 inhibitors: A high-throughput screening approach.推进TRIP13抑制剂的开发:一种高通量筛选方法。
SLAS Discov. 2025 Jun;33:100233. doi: 10.1016/j.slasd.2025.100233. Epub 2025 Apr 12.
3
Chromosome Missegregation Triggers Tumor Cell Pyroptosis and Enhances Anti-Tumor Immunotherapy in Colorectal Cancer.

本文引用的文献

1
TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.TRIP13损害有丝分裂检查点监测,与多发性骨髓瘤的不良预后相关。
Oncotarget. 2017 Apr 18;8(16):26718-26731. doi: 10.18632/oncotarget.14957.
2
Role of CCT chaperonin in the disassembly of mitotic checkpoint complexes.CCT 热休克蛋白在有丝分裂检验点复合物解体中的作用。
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):956-961. doi: 10.1073/pnas.1620451114. Epub 2017 Jan 17.
3
Conformation-specific anti-Mad2 monoclonal antibodies for the dissection of checkpoint signaling.
染色体错分离引发肿瘤细胞焦亡并增强结直肠癌的抗肿瘤免疫治疗
Adv Sci (Weinh). 2025 Mar;12(12):e2409769. doi: 10.1002/advs.202409769. Epub 2025 Feb 4.
4
TSG101 depletion dysregulates mitochondria and PML NBs, triggering MAD2-overexpressing interphase cell death (MOID) through AIFM1-PML-DAXX pathway.TSG101 缺失会扰乱线粒体和 PML NBs,通过 AIFM1-PML-DAXX 途径触发 MAD2 过表达的有丝分裂期细胞死亡(MOID)。
Cell Death Dis. 2024 Nov 17;15(11):838. doi: 10.1038/s41419-024-07229-w.
5
TRIP13: A promising cancer immunotherapy target.TRIP13:一个有前景的癌症免疫治疗靶点。
Cancer Innov. 2024 Oct 11;3(6):e147. doi: 10.1002/cai2.147. eCollection 2024 Dec.
6
Targeting TRIP13 for overcoming anticancer drug resistance (Review).靶向 TRIP13 克服抗癌药物耐药性(综述)。
Oncol Rep. 2023 Nov;50(5). doi: 10.3892/or.2023.8639. Epub 2023 Oct 6.
7
Optimized whole-genome CRISPR interference screens identify ARID1A-dependent growth regulators in human induced pluripotent stem cells.优化全基因组 CRISPR 干扰筛选鉴定人类诱导多能干细胞中 ARID1A 依赖性生长调节剂。
Stem Cell Reports. 2023 May 9;18(5):1061-1074. doi: 10.1016/j.stemcr.2023.03.008. Epub 2023 Apr 6.
8
Development of a novel BRCAness score that predicts response to PARP inhibitors.一种预测对PARP抑制剂反应的新型BRCAness评分的开发。
Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.
9
TRIP13/FLNA Complex Promotes Tumor Progression and Is Associated with Unfavorable Outcomes in Melanoma.TRIP13/FLNA复合物促进肿瘤进展并与黑色素瘤的不良预后相关。
J Oncol. 2022 Oct 11;2022:1419179. doi: 10.1155/2022/1419179. eCollection 2022.
10
Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.肝癌中 Trip13 的耗竭诱导脂质生成反应,有助于 Plin2 依赖性有丝分裂细胞死亡。
Adv Sci (Weinh). 2022 Oct;9(29):e2104291. doi: 10.1002/advs.202104291. Epub 2022 Aug 28.
用于剖析检查点信号传导的构象特异性抗Mad2单克隆抗体。
MAbs. 2016 May-Jun;8(4):689-97. doi: 10.1080/19420862.2016.1160988. Epub 2016 Mar 17.
4
TRIP13 Regulates Both the Activation and Inactivation of the Spindle-Assembly Checkpoint.TRIP13调节纺锤体组装检查点的激活与失活。
Cell Rep. 2016 Feb 9;14(5):1086-1099. doi: 10.1016/j.celrep.2016.01.001. Epub 2016 Jan 28.
5
Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).发现一种一流的、强效、选择性且口服生物可利用的p97 AAA ATP酶抑制剂(CB-5083)。
J Med Chem. 2015 Dec 24;58(24):9480-97. doi: 10.1021/acs.jmedchem.5b01346. Epub 2015 Dec 4.
6
Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.靶向AAA型ATP酶p97作为一种通过破坏蛋白质稳态来治疗癌症的方法。
Cancer Cell. 2015 Nov 9;28(5):653-665. doi: 10.1016/j.ccell.2015.10.002.
7
TRIP13PCH-2 promotes Mad2 localization to unattached kinetochores in the spindle checkpoint response.TRIP13PCH-2在纺锤体检查点反应中促进Mad2定位于未附着的动粒。
J Cell Biol. 2015 Nov 9;211(3):503-16. doi: 10.1083/jcb.201505114. Epub 2015 Nov 2.
8
The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics.纺锤体组装检验点信号动力学的分子生物学。
Curr Biol. 2015 Oct 19;25(20):R1002-18. doi: 10.1016/j.cub.2015.08.051.
9
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.利用纳升液滴对单个细胞进行高度并行的全基因组表达谱分析。
Cell. 2015 May 21;161(5):1202-1214. doi: 10.1016/j.cell.2015.05.002.
10
TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switching.TRIP13是一种蛋白质重塑的AAA+ATP酶,可催化MAD2构象转换。
Elife. 2015 Apr 28;4:e07367. doi: 10.7554/eLife.07367.